Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension

被引:4
作者
Ruilope, LM [1 ]
Segura, J [1 ]
机构
[1] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
关键词
cardiovascular disease; hypertension; risk assessment;
D O I
10.1016/j.clinthera.2005.10.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Accurate assessment of cardiovascular disease (CVD) risk in patients with hypertension is important when planning appropriate treatment of modifiable risk factors. The causes of CVD are multifactorial, and hypertension seldom exists as an isolated risk factor. Classic models of risk assessment are more accurate than a simple counting of risk factors, but they are not generalizable to all populations. In addition, the risk associated with hypertension is graded, continuous, and independent of other risk factors, and this is not reflected in classic models of risk assessment. Objective: This article is intended to review both classic and newer models of CVD risk assessment. Methods: MEDLINE was searched for articles published between 1990 and 2005 that contained the terms cardiovascular disease, hypertension, or risk assessment. Articles describing major clinical trials, new data about cardiovascular risk, or global risk stratification were selected for review. Results: Some patients at high long-term risk for CVD events (eg, patients aged <50 years with multiple risk factors) may go untreated because they do not meet the absolute risk-intervention threshold of 20% risk over 10 years with the classic model. Recognition of the limitations of classic risk-assessment models led to new guidelines, particularly those of the European Society of Hypertension-European Society of Cardiology. These guidelines view hypertension as one of many risk and disease factors that require treatment to decrease risk. These newer guidelines include a more comprehensive range of risk factors and more finely graded blood pressure ranges to stratify patients by degree of risk. Whether they accurately predict CVD risk in most populations is not known. Evidence from the Valsartan Ant1hypertensive Long-term Use Evaluation (VALUE) study, which stratified patients by several risk and disease factors, highlights the predictive value of some newer CVD risk assessments. Conclusion: Modern risk assessments, which include blood pressure along with a wide array of modifiable risk factors, may be more accurate than classic models for CVD risk prediction.
引用
收藏
页码:1658 / 1668
页数:11
相关论文
共 50 条
  • [31] Using the Framingham model to predict heart disease in the United Kingdom: retrospective study
    Ramachandran, S
    French, JM
    Vanderpump, MPJ
    Croft, P
    Neary, RH
    [J]. BRITISH MEDICAL JOURNAL, 2000, 320 (7236) : 676 - 677
  • [32] The rationale for differing national recommendations for the treatment of hypertension
    Ramsay, LE
    Wallis, EJ
    Yeo, WM
    Jackson, PR
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (06) : 79S - 88S
  • [33] MULTIPLE EFFECTS OF CALCIUM ENTRY BLOCKERS ON RENAL-FUNCTION IN HYPERTENSION
    ROMERO, JC
    RAIJ, L
    GRANGER, JP
    RUILOPE, LM
    RODICIO, JL
    [J]. HYPERTENSION, 1987, 10 (02) : 140 - 151
  • [34] Guidelines for antihypertensive therapy: Problems with a strategy based on absolute cardiovascular risk
    Simpson, FO
    [J]. JOURNAL OF HYPERTENSION, 1996, 14 (06) : 683 - 689
  • [35] Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy - Findings for 5 large cohorts of young adult and middle-aged men and women
    Stamler, J
    Stamler, R
    Neaton, JD
    Wentworth, D
    Daviglus, ML
    Garside, D
    Dyer, AR
    Liu, KA
    Greenland, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2012 - 2018
  • [36] Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
  • [37] Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality - The framingham heart study 1950 to 1990
    Sytkowski, PA
    DAgostino, RB
    Belanger, AJ
    Kannel, WB
    [J]. CIRCULATION, 1996, 93 (04) : 697 - 703
  • [38] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    Turner, RC
    Holman, RR
    Cull, CA
    Stratton, IM
    Matthews, DR
    Frighi, V
    Manley, SE
    Neil, A
    McElroy, K
    Wright, D
    Kohner, E
    Fox, C
    Hadden, D
    Mehta, Z
    Smith, A
    Nugent, Z
    Peto, R
    Adlel, AI
    Mann, JI
    Bassett, PA
    Oakes, SF
    Dornan, TL
    Aldington, S
    Lipinski, H
    Collum, R
    Harrison, K
    MacIntyre, C
    Skinner, S
    Mortemore, A
    Nelson, D
    Cockley, S
    Levien, S
    Bodsworth, L
    Willox, R
    Biggs, T
    Dove, S
    Beattie, E
    Gradwell, M
    Staples, S
    Lam, R
    Taylor, F
    Leung, L
    Carter, RD
    Brownlee, SM
    Fisher, KE
    Islam, K
    Jelfs, R
    Williams, PA
    Williams, FA
    Sutton, PJ
    [J]. LANCET, 1998, 352 (9131) : 837 - 853
  • [39] *UKPDS GROUP, 1999, BMJ-BRIT MED J, V318, P29
  • [40] Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population
    Wallis, EJ
    Ramsay, LE
    Haq, IU
    Ghahramani, P
    Jackson, PR
    Rowland-Yeo, K
    Yeo, WW
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7236): : 671 - 676